Figure 7.
Figure 7. Bortezomib alters expression of Bax in CTCL cell lines and tumoral cells from patients with Sézary syndrome. SeAx cells, HuT-78 cells, and PBLs from patients with Sézary syndrome were treated with or without increasing concentrations of bortezomib (10-40 nM) for 48 hours. Expression of Bcl-2 family members was analyzed after Western blotting, using the indicated antibodies (Bcl-2, Bcl-xl, Bid Bax, and p53). The membrane was stripped and reprobed for expression of GAPDH to control for loading (A). The graph (B) shows the relative modifications of protein expression after 20 and 40 nM bortezomib, in comparison with control untreated cells, which were arbitrarily set as 1 (mean increase ± SD, n = 12). *Statistically significant increase as compared to untreated samples.

Bortezomib alters expression of Bax in CTCL cell lines and tumoral cells from patients with Sézary syndrome. SeAx cells, HuT-78 cells, and PBLs from patients with Sézary syndrome were treated with or without increasing concentrations of bortezomib (10-40 nM) for 48 hours. Expression of Bcl-2 family members was analyzed after Western blotting, using the indicated antibodies (Bcl-2, Bcl-xl, Bid Bax, and p53). The membrane was stripped and reprobed for expression of GAPDH to control for loading (A). The graph (B) shows the relative modifications of protein expression after 20 and 40 nM bortezomib, in comparison with control untreated cells, which were arbitrarily set as 1 (mean increase ± SD, n = 12). *Statistically significant increase as compared to untreated samples.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal